No photo of Jeffrey Alan Sosman

View Scopus Profile

Jeffrey Alan Sosman

  • 65362 Citations
1976 …2023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Training Experience

1982Internship, University of Chicago Hospitals
1985Residency, University of Chicago Hospitals
1986Residency, University of Wisconsin Hospital & Clinics
1989Fellowship, University of Wisconsin Hospital & Clinics

Education/Academic qualification

MD, Albert Einstein College

… → 1981

Research interests

  • Genomic Medicine/Personalized Medicine
  • Immunology
  • Kidney Cancer / Urinary Tract Cancer
  • Skin Cancer

Fingerprint Dive into the research topics where Jeffrey Alan Sosman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #CA013-004: A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Sosman, J. A.

Bristol-Myers Squibb Company

3/10/20 → 3/10/23

Project: Research project

Prot #CA209-8Y8: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors

Sosman, J. A.

Bristol-Myers Squibb Company

2/5/20 → 2/5/23

Project: Research project

Prot #CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent or In Combination With Ciforadenant, with Pembrolizumab, And With Ciforadenant Plus Pembrolizumab In Adult Subjects With Advanced Ca

Sosman, J. A.

Corvus Pharmaceuticals, Inc.

12/20/19 → 12/20/22

Project: Research project

An In Silico, Medical Record-based Model for Understanding the INitiation of Autoimmune Events (IMMUNE)

Furmanchuk, A., Kho, A. N., Luo, Y., Sosman, J. A. & Walunas, T. L.

National Institute of Arthritis and Musculoskeletal and Skin Diseases

9/17/19 → 8/31/20

Project: Research project

    • Prot #16-214-02: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignan

    Sosman, J. A. & Villaflor, V. M.

    Covance Inc., Nektar Therapeutics

    3/20/19 → 3/20/22

    Project: Research project

    Research Output

    Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

    Wang, L. X., Quach, H. T., Moodabigil, N. V., Davis, E. J., Sosman, J. A., Dusetzina, S. B. & Johnson, D. B., Jan 15 2020, In : Cancer. 126, 2, p. 322-328 7 p.

    Research output: Contribution to journal › Article

    • Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon Alfa-2b for resected high-risk melanoma: North American Intergroup E1609

    Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., Koon, H. B., Lawrence, D. P., Kendra, K. L., Minor, D. R., Lee, C. B., Albertini, M. R., Flaherty, L. E., Petrella, T. M., Streicher, H., Sondak, V. K. & 1 others, Kirkwood, J. M., Feb 20 2020, In : Journal of Clinical Oncology. 38, 6, p. 567-575 9 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

    Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J. E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., Barker, K., Liang, Y., Warren, S., Beechem, J. M., Menzies, A. M., Tio, M., Long, G. V., Cohen, J. V., Guidon, A. C., O’Hare, M. & 13 others, Chandra, S., Chowdhary, A., Lebrun-Vignes, B., Goldinger, S. M., Rushing, E. J., Buchbinder, E. I., Mallal, S. A., Shi, C., Xu, Y., Moslehi, J. J., Sanders, M. E., Sosman, J. A. & Balko, J. M., Aug 1 2019, In : Nature Medicine. 25, 8, p. 1243-1250 8 p.

    Research output: Contribution to journal › Letter

    • 4 Scopus citations

    Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

    Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

    Research output: Contribution to journal › Letter

    A Time to Ignore “No Meat, No Treat”

    Kruser, T. J. & Sosman, J. A., Oct 1 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 2, p. 245-246 2 p.

    Research output: Contribution to journal › Letter